Belatacept after a kidney transplant: Minor added benefit for certain patients
Belatacept (trade name Nulojix) has been approved since June 2011 to prevent a rejection reaction of the body to the donor organ (transplant) in adults who have received a kidney transplant. The Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).
The assessment showed an indication of a minor added benefit of belatacept in adults with transplants from donors who had been selected according to the so-called standard criteria. Serious side effects such as urinary tract infections or pneumonia occurred less frequently in these patients and they also discontinued treatment due to side effects less often.
In patients who received transplants from donors who had been selected according to extended criteria (in this case, only deceased donors, who could also have been older and could have had certain accompanying diseases), no relevant differences could be found between the treatment with belatacept or with the comparator therapy, cyclosporine A. That means an added benefit of belatacept is not proven for these patients.
Belatacept in comparison with cyclosporine A
The immunosuppressant belatacept suppresses the immune system and thereby the natural defence reaction of the body to foreign tissue. Immunosuppressive drugs have to be taken long-term after a transplant in order to prevent the donor kidney being rejected after transplantation.
The appropriate comparator therapy used for the early benefit assessment was cyclosporine A. Both belatacept and cyclosporine A are given in combination with corticosteroids and a mycophenolic acid. Belatacept is given as an infusion (intravenously) into the bloodstream, whereas cyclosporine A is administered as a tablet.
Different donor characteristics
In both of the studies that were part of the approval of the drug and which were included in the benefit assessment, treatment with belatacept was compared with cyclosporine A. All participants in the studies were also treated with corticosteroids, with mycophenolate mofetil and, at the start of treatment, with the antibody basiliximab.
The main difference between the two studies was in the characteristics of the donors. In Study IM103008, adults were investigated who received a kidney from a donor classified according to standard criteria (Standard Criteria Donors, SCD). Here, about half of the organs came from living donors, the other half from deceased donors (for example after a fatal accident).
In Study IM103027, the donors had been selected according to so-called extended criteria (Extended Criteria Donors, ECD) and only organs from deceased donors were transplanted. ECD means that, for example, older donors over 60 years of age or younger ones with certain accompanying diseases can also be selected. In both studies, the patients were treated for 36 months. Since treatment with belatacept is long-term, IQWiG based its assessment chiefly on the results of the entire study period.
Added benefit only for patients with transplants from donors selected according to standard criteria
No added benefit of belatacept in comparison with cyclosporine A could be derived from the study data for adult patients who received a kidney transplant from a donor selected according to extended criteria (ECD).
For adult patients with a kidney transplant from a donor selected according to standard criteria (SCD), there was in each case an indication of lesser harm from belatacept for the outcome criteria "serious adverse events" and for "treatment discontinuations due to adverse events". However, because the differences between the treatment options are small, IQWiG rates the added benefit of belatacept compared with cyclosporine A in the lower category, namely as minor.
In terms of other outcome criteria relevant to patients, such as mortality, transplant loss, cardiovascular or renal diseases, the occurrence of diabetes or a disease of the lymphatic tissue after transplantation, the development of tumours, infections as well as the quality of life, IQWiG could not identify any other advantages or disadvantages of belatacept in comparison with cyclosporine A.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure which provides further information and can result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
More information: www.gesundheitsinformation.de/
- New drug for kidney transplant recipients effective in humans Feb 17, 2010 | not rated yet | 0
- Transplant drug preserves kidneys, avoids toxicity Mar 03, 2010 | not rated yet | 0
- Transplant drug two-year study outcomes show superior kidney function May 03, 2010 | not rated yet | 0
- Belimumab for lupus erythematosus: Added benefit not proven Aug 29, 2012 | not rated yet | 0
- Added benefit of fampridine is not proven Aug 29, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications 17 hours ago | not rated yet | 0
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications May 23, 2013 | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications May 23, 2013 | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
17 hours ago | 5 / 5 (4) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
9 hours ago | not rated yet | 1
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
17 hours ago | 5 / 5 (1) | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
17 hours ago | not rated yet | 0
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
May 20, 2013 | 4.8 / 5 (30) | 9 |